| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Ramachandra Sumant serves as a Director at LYEL. Across recent SEC filings that breaks down to 1 buy and 0 sells. Those positions are worth an estimated $115K at current prices.
The biggest single holding is LYEL (~$115K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 200,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 21, 2025 | LYEL Lyell Immunopharma, Inc. | Director | Buy | 200,000 | $0.58 | $115,220.00 | New | -24.9% | +65.3% |